S1098
Clinical – Upper GI
ESTRO 2026
A total of 64 lesions were treated in 56 patients, including 10 lesions in the central zone (within 2cm of the central biliary tree or major hepatic vessels) and 12 lesions close to bowel. All were CP A (A5 86%, A6 14%). Median tumour size was 23.5mm (range 7-55mm) with 25% ≥ 30mm. Median follow-up was 10.6 months (range 0.7-28.2 months).Median mean liver dose (MLD) was 7.93 Gy (range 1.34 -14.97Gy). Median normal liver volume was 1599.33cm3 (range 806.01 - 2894.47 cm3), with median liver V10Gy 28.3% (range 9.4-54.2%) and median D700 4.20Gy (range 0.38– 14.78Gy).Estimated LC rate at 12 months was 88.8% (95% CI: 75-95%). Out of five (7.8%) in-field recurrences, four had concurrent multifocal intrahepatic or extrahepatic progression. Higher BED (>100Gy) and tumours <30mm showed a trend towards improved LC with no statistical significance.Three patients (5%) experienced a ≥ 2 points deterioration in CP score post treatment, with no clear association between MLD and hepatic decompensation. No 30-day treatment-related mortality occurred. Conclusion: Outcomes following SABR treatment in our regional HCC centre show an acceptable safety profile with LC rates comparable to current literature. Further studies elucidating key prognostic features are needed to guide optimal patient selection and help establish SABR’s place in the HCC treatment paradigm. References: 1. Shanker MD, Pereshin Moodaley, Soon W, Liu HY, Yoo Young Lee, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta - analysis of local control, survival and toxicity outcomes. Journal of medical imaging and radiation oncology. 2021 Aug 15;65(7):956–68.2. Diez P, Hanna GB, Aitken K, N. van As, Carver A, Colaco RJ, et al. UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clinical Oncology. 2022 Mar 1;34(5):288–300. Keywords: Liver cancer, SABR, clinical outcomes Prospective quality-of-life and dosimetric correlates in esophageal cancer treated with radical or neoadjuvant chemoradiotherapy. Cristina Morón Jiménez, Carlos Camacho Fuentes, Claudia Díaz Silvera, Marta Pérez Cobos, Sara Pérez Mata, Laura Guzmán Gómez, Jesús Olivera Vegas, Jose C Vara Santos, Walter Armando Vasques Rivas, Leticia Del Campo Rodríguez-Ponga, Patricia Salgado González, Mónica Carlota Barnés Hernández, Javier Luna Tirado Digital Poster 3296
dose per fraction—a modifiable factor—was the strongest predictor for EDP, while traditional clinical factors were not. This suggests dose selection may be acting as a surrogate indicator for clinician-perceived aggressive tumor biology not captured by standard variables. Our data caution against using lower-dose SBRT regimens in this setting. This highlights the urgent need to integrate new biomarkers to improve patient selection for ablative therapy. Keywords: SBRT, liver metastases, distant recurrence hepatocellular carcinoma: Outcomes, safety and dosimetric correlates from a single-centre study May Myat Noe Win 1 , Bosire Oroko 1 , Gabriel Naylor- Leyand 2 , Andre Lopes 2 , Yishen Wang 1 , Melissa Lovegrove 3 , Anne Anderson 3 , James Barber 3 , Frida Hazara 3 , Katia Pasciuti 3 , Arunansu Kar 1 , Swee-Ling Wong 1 1 Oncology Department, Royal Free London NHS Foundation Trust, London, United Kingdom. 2 Cancer Research UK & UCL Cancer Trials Centre, University College London, London, United Kingdom. 3 Radiotherapy Department, Royal Free London NHS Foundation Trust, London, United Kingdom Digital Poster 3285 Stereotactic ablative radiotherapy for Purpose/Objective: Stereotactic Ablative Radiotherapy (SABR) is increasingly used to treat hepatocellular carcinoma (HCC) in patients unsuitable for resection or other locoregional therapies and as a bridge to liver transplantation. Patient selection is important and baseline hepatic function, tumour size and location are critical considerations [1]. We report our single- centre, real-world data of SABR for HCC, focusing on treatment outcomes, safety and dosimetric correlates. Material/Methods: A retrospective review was performed on patients with HCC treated with SABR between February 2023 and May 2025. Prescribed doses were 30-50Gy in 3-5 fractions. Liver dose constraints and tissue tolerances adhered to the UK SABR consortium guidance [2]. Patients had contrast enhanced 3D-CT and 4D-CT scans and were immobilised using abdominal compression where tolerated. Nine patients required fiducial markers. Alternative surrogates (eg.external liver contours) were used in others. Treatment was delivered free-breathing with 4D-CBCT motion verification.Local control (LC) was assessed via cross- sectional imaging. Child-Pugh (CP) scores were recorded pre- and post-SABR. The effect of biologically effective dose (BED) and tumour size on LC rate was assessed using univariate Cox regression. Results:
Made with FlippingBook - Share PDF online